LUGPA 2026 Annual Meeting Full Recap
LUGPA's 18th Annual Meeting brought independent urologists, practice administrators, industry leaders, and policymakers together in Chicago from November 5–7, 2026, for three days of connection, learning, and leadership. Across sessions, policy discussions, CME programming, and breakout groups, attendees explored ways to strengthen autonomy, advance patient care, and empower the next generation of urology leaders. The meeting drew 1,400 attendees, which is the largest to date.
Day 1: CME and Operational Strategy
LUGPA 2026 kicked off Thursday, November 5, with the Practice Administrators Workshop led by Kirsten Anderson, MHA, CMPE, Chair of the LUGPA Practice Administrators Committee. The interactive workshop focused on operational and business strategies, including coding and billing updates, EMR transition pearls and pitfalls, AI integration, and maximizing ancillary revenue streams.
The afternoon CME program, “Precision in Practice: Advancing Urologic Care Through Innovation and Evidence,” was led by Drs. Gordon Brown and Jason Hafron. The sessions explored advances across bladder, prostate, and benign urology, covering topics such as PSMA theranostics, PTEN and emerging biomarkers, artificial intelligence in pathology, BPH centers of excellence, neuromodulation, and histotripsy. The evening concluded with a networking reception in the exhibit hall for attendees and industry partners.
Two working groups for research directors and coordinators as well as radiation and oncology services also met. During the Radiation & Oncology Services session, Travis Mendel, MD spoke on how artificial intelligence is being successfully implemented in physician-led practices including how it is improving clinical efficiency, billing and revenue cycles and phone and patient access. "Efficiency enhancements will make AI more prevalent in private practice in the coming years," said Travis. Yet, physicians need to continue to think critically about AI and continue to be at the center of patient decision making. "AI will make it more efficient to read a note, but the physician ultimately makes the decisions for the patient."
Day 2: Advocacy, Autonomy, and Practice Innovation
Friday, November 6, focused heavily on health policy, legislative updates, and practice sustainability amidst ongoing industry consolidation, prior authorization burdens, and Medicare fee schedule changes.
The opening general session included remarks from Benjamin Lowentritt, MD, LUGPA Secretary and Chair of the Annual Meeting and Scott B. Sellinger, MD, LUGPA President.
The LUGPA Health Policy Forum and Political Affairs Update included an overview of the impact of the mid-term elections from Tracy Spicer, Founding Partner of Avenue Solutions, John McManus of the McManus Group, Josh Langston, MD, CEO of Urology of Virginia and Gary Kirsh, MD Chief Executive Office of Cardiovascular Logistics.
"Advocacy is important," said Kirsh. "The amount of turnover in Congress is unprecedented with as many as 100 new members."
The speakers emphasized the important role everyone in urology can play in communicating LUGPA's legislative priorities, which include: 1) addressing physician payment, 2) prior authorization reform, 3) protecting cancer care and 4) site neutral payment and 340b reform.
Sessions throughout the day examined critical healthcare policy issues, including site-neutral payments, prior authorization reform, artificial intelligence integration, and benchmarking metrics. Speakers emphasized the essential role of independent practices in preserving patient access and quality care.
LUGPA's President, Celeste Kirschner, highlighted new programs and initiatives for members including a new LUGPA Podcast, Urology Now, produced by MedLive, state advocacy initiatives, a physician mentorship toolkit, and new on-demand offerings on LUGPA Learn.
"We are building an organization that can do more for our members," said Kirschner. "The more members contribute to LUGPA, the more we can do together."
Afternoon breakouts tackled practice management and leadership development, providing practical strategies for navigating economic headwinds, workforce shortages, and practice growth.
Day 3: Keynote Perspectives, Policy, and Leadership
Saturday, November 7, Ruchika Talwar, MD presented "The Future-Ready Urologist: Navigating Healthcare's Biggest Shifts." She discussed three major trends in healthcare including changes in Medicare Advantage, vertical integration, and corporate investments.
"We need to pay attention to the new ways of delivering healthcare and be involved in shaping the future of our industry," urged Talwar.
LUGPA congratulated the following leaders on their new officer roles: Jeffrey Spier, MD, as president; Benjamin Lowentritt, MD, FACS, as president-elect; Scott Sellinger, MD, as immediate past president; David Morris, MD, as secretary; Evan Goldfischer, MD, MBA, CPI, as a member-at-large. LUGPA also welcomed two new members-at-large to the Board of Directors: Tamra Lewis, MD, FACS and Brooke Edwards, MD.
Incoming president, Jeffrey Spier, MD, also welcomed new LUGPA Board Members and addressed attendees:
"The last few years have brought tremendous change," said Spier. "We’ve seen massive industry shifts, consolidation, the growth of hospital employment, and an increasingly complex business environment that have left many physicians and practice leaders asking important questions. Where do we fit? How do we preserve our voice? And what will the future hold for independent practice?
There have been moments of uncertainty—moments when colleagues wondered whether they were falling behind or whether the practice they had worked so hard to build could thrive in this dynamic healthcare environment. But I stand here today with confidence—not because every challenge is behind us, but because we don’t have to face those challenges alone. Through all that change, LUGPA has been—and must remain—our common ground."
Additionally, a bipartisan legislative and regulatory analysis titled “A Conversation with Chris Christie and David Axelrod.” The session offered a deep dive into the political landscape, shifting governance, and how upcoming policy decisions impact the long-term viability of independent medicine.
The meeting concluded with a focus on leadership development, celebrating the strength and unity of community-based independent urology practices nationwide.
A Meeting Defined by Connection
From packed CME sessions to policy debates and dynamic exhibit hall networking, the 2026 LUGPA Annual Meeting embodied the power of collaboration—demonstrating how independent urologists continue to shape the future of patient care.
Media Coverage to date
- 10-28-26 Urology Times LUGPA 2026: Midterms, AI, and ancillary services take center stage
- 10-28-26 MDLinx Bladder cancer treatment is changing fast. Can urologists keep up?
- 10-28-26 MDLinx Pathologic response is rising in MIBC: Is it too soon to spare the bladder?
- 10-28-26 MDLinx From target to toxicity: Navigating ADCs in bladder cancer care
- 11-5-26 Renal & Urology News LUGPA’s Annual Meeting Is Helping Urology Practices Thrive
- 11-5-26 Renal & Urology News Conducting Clinical Trials Within Community Urologic Practice
- 11-5-26 Urology Times William Huang, MD, discusses the potential of histotripsy for renal tumors
- 11-5-26 Urology Times Durvalumab plus BCG may best serve patients with high-grade T1 NMIBC
- 11-5-26 Urology Times Treating MIBC as a systemic disease reshapes bladder preservation
- 11-5-26 OncLive BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
- 11-6-26 Urology Times Talazoparib triplet joins treatment options for HRR-mutated mHSPC
- 11-6-26 Urology Times Treatment intensification in mHSPC: Balancing disease burden, biomarkers, and toxicity
- 11-6-26 Urology Times Q&A: Gary Kirsh, MD, on health policy for independent urology
- 11-6-26 Urology Times Patient priorities guide treatment choice in BCG-unresponsive NMIBC
- 11-6-26 Urology Times PTEN loss: From biomarker to treatment strategy in mHSPC
- 11-6-26 OncLive Enfortumab Vedotin Plus Pembrolizumab Expands Bladder Preservation in MIBC
- 11-6-26 OncLive PSMA Radioligand Therapy Spans Metastatic Prostate Cancer as Next-Generation Theranostics Emerge
- 11-6-26 OncLive Updated CAPItello-281 Data Support OS Advantage With Capivasertib in PTEN-Deficient mHSPC
- 11-6-26 OncLive Dr Garmezy on Personalizing Treatment Intensification in mHSPC
- 11-6-26 OncLive Dr Merrill on Selecting Patients for BCG Plus Durvalumab in High-Risk NMIBC
- 11-6-27 OncLive BCG-Unresponsive NMIBC Treatment Selection Requires Balancing Durability, Toxicity, and Patient Priorities
- 11-6-26 OncLive BCG Monotherapy Remains the Preferred First Move in BCG-Naive High-Risk NMIBC
- 11-7-27 Urology Times Modern BCG outperforms historic benchmarks in high-risk NMIBC
- 11-7-26 Small Business World Magazine LUGPA’s 18th Annual Meeting Highlights Clinical Advancements and Practice Resilience for Independent Urologists
- Read coverage of the meeting from Medscape.
|